This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


BTG plc

Drug Names(s): Sustained-release paclitaxel; Paclitaxel Aqueous Gel Injection

Description: OncoGel is a sustained-release version of paclitaxel, designed to provide high concentrations of paclitaxel at the tumour site while minimising exposure to other organs.

Taxol inhibits cell proliferation by stabilizing microtubules. Microtubules are cylindrical structures that form the basis of the cellular skeleton and are essential to the reproduction, growth, and spread of tumor cells. Normally, as a part of the mitotic process, microtubules are reorganized to form a spindle. Taxol binds tubulin, promoting polymerization and preventing de-polymerization of microtubules, resulting in cell death.

OncoGel News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug